Established in 1977, the Burzynski Clinic has grown to be a nationally and internationally recognized cancer center that provides advanced and cutting-edge cancer treatments.
For over 35 years, Dr. Burzynski’s cancer research and patient care has been inspired by the philosophy of the physician Hippocrates: ‘First, do no harm’. Therefore, our approach to treatment is ‘personalized’ in an attempt to maximize effectiveness and minimize side effects for each cancer patient.
In everything we do, we are proudly committed to these principles of cancer treatment and to continued cancer research. Our mission is to beat cancer.
Personalized cancer therapy utilizes an understanding of each patient’s genetic make-up to unravel the biology of their cancer. Using this information, our physicians attempt to identify treatment strategies that may be more effective and cause fewer side effects than would be expected with standard treatments. By performing genetic tests and analyses, our physicians customize treatment to each patient’s needs.
Personalized medicine may include the combination of targeted therapies with conventional therapy. It may also involve the use of investigational agents (Antineoplastons), as approved by the FDA. Patients and/or their caretakers receive training for administering all therapies at home, as well as nutritional counseling.
About Dr. Stanislaw R. Burzynski
burzynskiDr. Burzynski, a nationally and internationally recognized physician/investigator, pioneered the use of biologically active peptides for the treatment of cancer. In 1967, at the age of 24, Dr. Burzynski graduated first in his class of 250 students from the Medical Academy in Lublin, Poland. It was at this time that he identified naturally occurring human peptides, which were deficient in cancer patients. He concluded that these peptides played a role in preventing the growth of cancer cells. In 1968, he earned a PhD degree and became one of the youngest physician/investigators in Poland to hold both a MD and PhD degree.
Between 1970 and 1977, he received funding from the National Cancer Institute (NCI) for his work as an investigator and Assistant Professor at the Baylor College of Medicine in Houston, TX. During this time he authored/coauthored 16 publications, including five detailing his work on naturally occurring human peptides and their effect on cancer – four of which were co-authored by investigators associated with the M.D. Anderson Cancer Center or the Baylor College School of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from the Baylor College of Medicine that acknowledged his contributions to the ‘Advancement of Medical Education, Research, and Health Care’.
In 1977 that the Burzynski Clinic was established in Houston, TX. Since then, more than 8,000 patients have received treatment at the clinic, including more than 2,300 cancer patients who have been treated in FDA reviewed and Institutional Review Board (IRB) approved clinical trials program of Antineoplastons, investigational agents that derived from Dr. Burzynski’s early investigations of naturally occurring human peptides. Currently, new FDA-reviewed Phase II and III clinical studies utilizing Antineoplastons are awaiting Institutional Review Board (IRB) approval prior to patient enrollment.
Dr. Burzynski has extensive experience treating cancer with combinations of targeted agents and the drug phenylbutyrate (PB), which targets multiple genetic abnormalities simultaneously.
Dr. Burzynski is the author/co-author of over 300 scientific publication/presentations. He has collaborated with investigators at the NCI, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, and the University of Turin Medical School in Italy, among others. He is a member of several prestigious organizations, including the American Association of Cancer Research (AACR), the Society for Neuroscience, the Society for Neuro-oncology, the Royal Medical Association (U.K.), and the Academy of Medical Ethics. As of June 2015, he held 244 patents in 35 countries covering 17 proprietary scientific inventions.
*This listing does not accept contributions